Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.38 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | DRD5 | P21918 | 1/20 | 0.38 |
| ▸ | HRH2 | P25021 | 1/20 | 0.38 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | HTR5A | P47898 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5434964 | 0.84 | NAAA (0.42) | SLC6A3CACNA1FDRD1DRD4DRD5 | |
| SCHEMBL12587782 | 0.84 | SLC18A3 (0.47) | SLC6A3CACNA1FDRD1DRD4DRD5 | |
| SCHEMBL14610742 | 0.76 | HTT (0.42) | SLC6A3CACNA1FDRD1DRD4DRD5 | |
| SCHEMBL523236 | 0.76 | HTT (0.42) | SLC6A3CACNA1FDRD1DRD4DRD5 | |
| SCHEMBL13707303 | 0.76 | DRD2 (0.53) | DRD4HTR2AHTR2CHTR7HRH1 | |
| SCHEMBL14610747 | 0.75 | FKBP1A (0.50) | SLC6A3CACNA1FDRD1DRD4DRD5 | |
| SCHEMBL522211 | 0.75 | FKBP1A (0.50) | SLC6A3CACNA1FDRD1DRD4DRD5 | |
| SCHEMBL13147963 | 0.73 | L3MBTL1 (0.44) | DRD4HTR2AHTR2CHRH1DRD3 | |
| SCHEMBL14500706 | 0.72 | NAAA (0.39) | SLC6A3CACNA1FDRD1DRD4DRD5 | |
| SCHEMBL28374990 | 0.70 | SLC18A3 (0.44) | SLC6A3CACNA1FDRD1DRD4DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9994520-B2 | Enzymatic process for the preparation of (S)-5-(4-fluoro-phenyl)-5-hydroxy-1morpholin-4-yl-pentan-1-one, an intermediate of ezetimibe and further conversion to ezetimibe | MYLAN LABORATORIES LIMITED (IN) | 2018-06-12 | — | — | US | disclosed |
| US-20160280642-A1 | ENZYMATIC PROCESS FOR THE PREPARATION OF (S)-5-(4-FLUORO-PHENYL)-5-HYDROXY- 1MORPHOLIN-4-YL-PENTAN-1-ONE, AN INTERMEDIATE OF EZETIMIBE AND FURTHER CONVERSION TO EZETIMIBE | MYLAN LABORATORIES LIMITED (IN) | 2016-09-29 | — | — | US | disclosed |
| US-9388440-B2 | Enzymatic process for the preparation of (S)-5-(4-fluoro-phenyl)-5-hydroxy-1morpholin-4-yl-pentan-1-one, an intermediate of Ezetimibe and further conversion to Ezetimibe | MYLAN LABORATORIES LIMITED (IN) | 2016-07-12 | — | — | US | disclosed |
| EP-2414529-A2 | ENZYMATIC PROCESS FOR THE PREPARATION OF (S)-5-(4-FLUORO-PHENYL)-5-HYDROXY- 1MORPHOLIN-4-YL-PENTAN-1-ONE, AN INTERMEDIATE OF EZETIMIBE AND FURTHER CONVERSION TO EZETIMIBE | Matrix Laboratories Ltd (IN) | 2012-02-08 | — | — | EP | disclosed |
| US-20120028316-A1 | ENZYMATIC PROCESS FOR THE PREPARATION OF (S)-5-(4-FLUORO-PHENYL)-5-HYDROXY- 1MORPHOLIN-4-YL-PENTAN-1-ONE, AN INTERMEDIATE OF EZETIMIBE AND FURTHER CONVERSION TO EZETIMIBE | MATRIX PHARMACORP PRIVATE LIMITED (IN) | 2012-02-02 | — | — | US | disclosed |
| WO-2010113175-A2 | ENZYMATIC PROCESS FOR THE PREPARATION OF (S)-5-(4-FLUORO-PHENYL)-5-HYDROXY- 1MORPHOLIN-4-YL-PENTAN-1-ONE, AN INTERMEDIATE OF EZETIMIBE AND FURTHER CONVERSION TO EZETIMIBE | MATRIX LABORATORIES LTD (IN) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028316-A1 | ENZYMATIC PROCESS FOR THE PREPARATION OF (S)-5-(4-FLUORO-PHENYL)-5-HYDROXY- 1MORPHOLIN-4-YL-PENTAN-1-ONE, AN INTERMEDIATE OF EZETIMIBE AND FURTHER CONVERSION TO EZETIMIBE | CES1, CMA1, CYP51A1 | SLC6A3 4746/4885CACNA1F 2291/4885DRD1 946/4885 |
| US-20160280642-A1 | ENZYMATIC PROCESS FOR THE PREPARATION OF (S)-5-(4-FLUORO-PHENYL)-5-HYDROXY- 1MORPHOLIN-4-YL-PENTAN-1-ONE, AN INTERMEDIATE OF EZETIMIBE AND FURTHER CONVERSION TO EZETIMIBE | TPSD1, PCSK9, PEPD | SLC6A3 4851/4885CACNA1F 2397/4885DRD1 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.